Nobilis Therapeutics and Submersible Systems Partner to Create a Portable Inhalation Device for Administration of NBTX-001, a Medical Gas-based Drug Candidate
by nobilistx | May 10, 2017 | Uncategorized | 0 comments
News
- Nobilis Therapeutics Presentation at CapCon Investor Conference December 8, 2020
- Nobilis Therapeutics to Present at CapCon 2020 Venture Conference November 4, 2020
- Nobilis Therapeutics is Granted a US Patent for its Invention “THERAPEUTIC IMMUNE MODULATION USING NOBLE GAS COMPOSITIONS” that covers its use in Autism Spectrum Disorder October 22, 2020
- Nobilis Therapeutics Announces FDA Clearance of IND to Commence Phase 2b Trial of NBTX-001 Inhaler for Treatment of Panic Disorder July 22, 2020
- Nobilis Therapeutics Announces IND Filing for a Phase 2b Clinical Trial of NBTX-001 Drug/Device Combination for Treatment of Panic Disorder June 23, 2020
Recent Posts
- Nobilis Therapeutics Presentation at CapCon Investor Conference
- Nobilis Therapeutics to Present at CapCon 2020 Venture Conference
- Nobilis Therapeutics is Granted a US Patent for its Invention “THERAPEUTIC IMMUNE MODULATION USING NOBLE GAS COMPOSITIONS” that covers its use in Autism Spectrum Disorder
- Nobilis Therapeutics Announces FDA Clearance of IND to Commence Phase 2b Trial of NBTX-001 Inhaler for Treatment of Panic Disorder
- Nobilis Therapeutics Announces IND Filing for a Phase 2b Clinical Trial of NBTX-001 Drug/Device Combination for Treatment of Panic Disorder
Archives
- December 2020
- November 2020
- October 2020
- July 2020
- June 2020
- May 2020
- April 2020
- February 2020
- January 2020
- December 2019
- November 2019
- September 2019
- August 2019
- July 2019
- January 2019
- December 2018
- August 2018
- June 2018
- May 2018
- February 2018
- January 2018
- December 2017
- October 2017
- June 2017
- May 2017
- April 2016
- March 2016
- January 2016
Recent Comments